January 23, 2020 – MEDITEST announces its merger with IBA Dosimetry in the French radiotherapy market.
IBA Dosimetry innovates in radiotherapy, proton therapy and diagnostic imaging with independent and integrated quality assurance solutions that are effective, intuitive and provide peace of mind for healthcare professionals and patients worldwide.
MEDITEST has become the exclusive distributor and service partner for the entire IBA range in the French market. This includes the new SMARTSCAN™ solutions, the comprehensive myQA® platform, and the myQA® Daily Morning solution. MEDITEST aims to address all dosimetry-related issues and needs in radiotherapy.
The partnership will be beneficial for all current and future MEDITEST E and IBA customers and members of the French radiotherapy community, thanks to the complementarity of the product and service ranges.
With IBA, MEDITEST wishes to pursue a common path to improve patient safety and the performance of quality assurance solutions in radiotherapy.
About IBA Dosimetry:
IBA Dosimetry GmbH is innovating in radiotherapy, proton therapy, and diagnostic imaging with independent and integrated quality assurance solutions that are efficient, intuitive, and provide peace of mind for healthcare professionals and patients worldwide. The myQA® Global QA platform is the backbone of these quality assurance solutions. IBA Dosimetry has over 220 employees worldwide and offices in Germany, France, China, and the USA. IBA Dosimetry is part of the IBA Group, a global medical technology company focused on developing integrated and innovative solutions for cancer diagnosis and treatment. More information is available at: www.iba-dosimetry.com